# Postmarketing Clinical Study on AO-128

> **NCT02287402** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 197 (actual)

## Conditions studied

- Impaired Glucose Tolerance (IGT)

## Interventions

- **DRUG:** AO-128

## Key facts

- **NCT ID:** NCT02287402
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2015-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287402, "Postmarketing Clinical Study on AO-128". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02287402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*